The explanation is that most CCSD-omphacites were strongly affected by recrystallisation, which took place above 600 degrees C during subduction up to its maximum temperature of similar to 750 degrees C and continued during exhumation above 600 degrees C into the regime of amphibolite facies for several tens of Ma. Garnet shows very rarely crystal defects, while amphiboles usually displayed dislocations and chain multiplicity faults. Rutile of one sample, which contained a few percent Fe, showed fully coherent, nano-sized

platelets (Guinier-Preston zones) parallel to (100) and (010). The existence of fluids during retrogression is documented by K-feldspar and analcime Barasertib in quartz.”
“The objective of this study was to determine the Rho inhibitor effect of body weight (BW) at slaughter and fattening intensity on carcass fatness and meat fatty acid profile in young Holstein-Friesian bulls. One-hundred bulls fattened on two levels of intensity a semi-intensive (SI) and an intensive (I) were used. Fattening

was carried out to BW of 500, 550, 600, 650 and 700 kg. Live ultrasound measurements were performed to determine back fat thickness. Carcass dressing percentage, carcass conformation and fatness, intramuscular fat content of m. longissimus dorsi and fatty acid profile (by gas chromatography) were determined after slaughter. Intensively fattened bulls were characterised by a greater carcass dressing percentage – by 1.17% on average, greater carcass conformation scores, greater external fat thickness Z-DEVD-FMK and a greater intramuscular fat content than bulls SI fattened. Fat from intensively fattened bulls contained higher levels of polyunsaturated fatty acids (PUFAs) – by 0.96/100 g on average. Semi-intensive fattening contributed to a decrease in the n-6/n-3 PUFA ratio and to a significant

increase in the concentrations of C18:2 and C20:4 fatty acids. Regardless of the fattening intensity, the n-6/n-3 ratio was greater in heavier animals. The best results were achieved when young Holstein-Friesian bulls were fattened intensively to BW of 650 kg.”
“BACKGROUND & AIMS: Patients with moderate to severe ileocolonic Crohn’s disease (CD) who received adalimumab induction and maintenance therapy had greater rates of mucosal healing than patients who received placebo after adalimumab induction therapy in a 52-week trial (EXTend the Safety and Efficacy of Adalimumab Through ENDoscopic Healing). We investigated whether this treatment also induced deep remission-a composite clinical and endoscopic end point. METHODS: Rates of deep remission, defined as the absence of mucosal ulceration and CD Activity Index scores less than 150, were compared between patients given continuous adalimumab and those given only induction therapy followed by placebo.